Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spero Therapeutics: Remodeling Antibiotics

This article was originally published in Start Up

Executive Summary

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Advertisement

Related Content

Venture Funding Deals: LAM Nabs $58m Series C One Year After $40m Round
Here To Stay: Inception Sciences Shows Why Build-To-Buy Works
Actavis’ Avycaz Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic
Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel